Macropore Inc. IR-Pages
MacroPore Biosurgery Awarded SBIR Grant from the NIH
Corporate-news announcement sent by DGAP.
The sender is solely responsible for the contents of this announcement.
——————————————————————————–
MacroPore Biosurgery Awarded SBIR Grant from the NIH
MacroPore Biosurgery Awarded SBIR Grant from the NIH to Study the Use of
Adipose-Derived Regenerative Cells for Treating Heart Attack
San Diego, CA, January 15, 2004 – MacroPore Biosurgery, Inc. (Frankfurt Stock
Exchange: XMP) (MacroPore) announced today it has been awarded a Fast Track
Phase I/II Small Business Innovation Research (SBIR) grant from the National
Institutes of Health (NIH) to study the role of adipose-derived regenerative
cells in treating myocardial infarction (heart attack). This research will be
conducted in collaboration with W. Robb MacLellan M.D. at the David Geffen
School of Medicine at the University of California, Los Angeles (U.C.L.A.).
MacroPore and its collaborators have shown that adipose tissue is a rich source
of autologous regenerative cells, which contain adult stem cells. The SBIR
studies are designed to evaluate the capacity of adipose-derived regenerative
cells to improve revascularization and regenerate damaged myocardial tissue
following a heart attack. By using adipose tissue as a cell source, MacroPore
intends to demonstrate that it can obtain therapeutically relevant quantities of
regenerative-capable cells in real-time.
“The limited ability of the adult heart to regenerate itself after an injury
such as heart attack frequently leads to heart failure or other complications,”
said Dr. MacLellan. “The research performed to date at MacroPore suggests that
regenerative cells purified from adipose tissue may represent a clinically
useful source of cells to promote myocardial regeneration in patients
immediately after a heart attack. This grant will allow us to continue our
collaboration with MacroPore and further accelerate this research.”
“MacroPore has gained a significant understanding of the potential clinical
applications for adipose-derived regenerative cells from our preclinical
studies,” said Christopher J. Calhoun, President and Chief Executive Officer of
MacroPore. “The receipt of this grant will provide funding to help advance our
development program.”
About MacroPore Biosurgery, Inc.
MacroPore Biosurgery (Frankfurt: XMP) (MacroPore) is the global leader in the
discovery and development of regenerative medicine technologies and therapies.
We are committed to improving the practice of medicine by creating innovative
products that address two important segments of medicine: spine and orthopedic
repair and cardiovascular disease. Our surgical implants, which represent one of
the latest advancements in spine and orthopedic medicine, are manufactured at
MacroPore and marketed exclusively through Medtronic Sofamor Danek.
Additionally, we are developing a cell-based therapy to regenerate damaged heart
muscle resulting from myocardial infarction. The approach will be based on a
cell-therapy system, currently under development, capable of isolating
regenerative cells from adipose tissue. For further information please visit our
web site http://www.macropore.com .
Kontakt:
Tom Baker
Media/U.S. Investors
Tel. +1-858-458-0900
tbaker@macropore.com
Stefanie Bacher
European Investors
Tel. +1-858-362-0365
sbacher@macropore.com
Cautionary Statement Regarding Forward-Looking Statements
This press release may include forward-looking statements regarding events and
trends which may affect MacroPore Biosurgery’s future operating results and
financial position. Such statements are subject to risks and uncertainties that
could cause MacroPore Biosurgery’s actual results and financial position to
differ materially. These risks and uncertainties are described (under the
heading “Risk Factors”) in our 2002 Annual Report which is available on our web
site. MacroPore Biosurgery assumes no responsibility to publicly release the
results of any revision of forward-looking statements to reflect events, trends
or circumstances after the date they are made.
end of message, (c)DGAP 15.01.2004
——————————————————————————–
WKN: 940682; ISIN: USU553961025; Index: NEMAX 50
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart
151630 Jän 04
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found